How to create a budget impact analysis to support our Belgian Price and reimbursement dossier? How to collect Belgian data for this budget impact analysis?
What managed entry agreement (MEA)/ price could be negotiated for our drug/medical device in Belgium?
Will our product end up in the same added value class after the legislative amendments for pricing & reimbursement in Belgium?
How to write the pricing & reimbursement dossier? We need support with submission of our pricing & reimbursement dossier in Belgium.
Does our health economic model meet the methodological Belgian recommendations? and how to implement our health economic model in the Belgian context?
Try our market access as a service
Innosens provides advanced services based on market access consulting on the Belgian pharmaceutical market. In the pharmaceutical industry, both technical and emotional aspects affect the strategy of a pharmaceutical company. Innosens likes to combine both aspects to provide a high quality pharmaceutical market access consulting service.Learn more
Early Access Program as a service
An early access program to medicines in Belgium is useful when a specific drug is not yet available to one or more patients who suffer from a chronic or serious illness and cannot be satisfactorily treated via any existing health care pathways.Learn more
Managed Entry Agreements (MEA)
A Managed Entry Agreement (MEA) is a confidential arrangement between a manufacturer and payer/provider that enables access to (coverage/reimbursement of) a health technology subject to specified conditions.Learn more
BeNeLuxA(Ir) as a service
BeNeLuxA(Ir) is a joint negotiation procedure for timely and affordable access to very specific innovative drugs in Belgium, The Netherlands, Luxembourg, Austria and Ireland. This can be applied with complex and rare (innovative) medicines, with a higher cost per patient and a relatively high budget impact.Learn more